Y u De-Chao, also known as Michael Yu, is the co-founder, chairman, and CEO of Innovent Biologics, a premier biopharmaceutical company in China. A scientist-entrepreneur, Yu holds a PhD in molecular genetics from the Chinese Academy of Sciences and completed postdoctoral research in pharmaceutical chemistry at the University of California, San Francisco. His extensive background includes inventing oncolytic virus products and leading drug discovery efforts at major international firms before founding Innovent in 2011.

Under his leadership, Innovent Biologics has developed a robust pipeline of high-quality biopharmaceuticals aimed at treating cancer and autoimmune diseases. The company listed on the Hong Kong Stock Exchange in 2018 and has formed strategic partnerships with global giants like Eli Lilly. Yu is widely recognized for bridging the gap between Chinese biotech innovation and global standards, driving the development of affordable, world-class medicines for patients.